The Majority of Surveyed Gastroenterologists Have a Positive Reaction to Takeda's Cell Adhesion Molecule Inhibitor Entyvio

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 09/29/2014.
  • Additional Information
    • Alternate Title:
      MA-DecisionResources
    • Subject Terms:
      Massachusetts
    • Abstract:
      BURLINGTON, Mass., Sept. 29, 2014 /PRNewswire/ -- Decision Resources Group finds that one month post-launch, the majority of surveyed gastroenterologists are aware and familiar with Entyvio as a new therapy for the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease (CD). According to surveyed gastroenterologists, the most commonly cited advantage of Entyvio compared with other currently available biologic treatments includes its different mechanism of action. One month post-launch, less than 20 percent of surveyed gastroenterologists report prescribing Entyvio to their UC and/or CD patients. [ABSTRACT FROM PUBLISHER]